A Multicenter Randomized Double-Masked Study Comparing Preservative-free Brimonidine Tartrate Ophthalmic Solution 0.025% with LUMIFY® 0.025% for Ocular Redness in Adults

Abstract Introduction Ocular redness is common, can affect quality of life, and can be relieved by short-term use of topical adrenergic receptor (AR) agonists. Brimonidine tartrate ophthalmic solution 0.025% (LUMIFY® 0.025%) is the first α2-AR-selective agonist approved for ocular redness. The prese...

Cijeli opis

Bibliografski detalji

Glavni autori:	Melissa Toyos, Melinda DiVito, Elisabeth M. Messmer, Selina McGee, Jared Peterson, Assem Patel, Guruprasad Pattar, David G. Evans, Patrick M. Vollmer, Gina Wesley
Format:	Artigo
Jezik:	Inglês
Izdano:	Adis, Springer Healthcare 2025-07-01
Serija:	Ophthalmology and Therapy
Teme:	Brimonidine Benzalkonium chloride Brimonidine tartrate ophthalmic solution 0.025% Hyperemia LUMIFY Ocular redness
Online pristup:	https://doi.org/10.1007/s40123-025-01194-z
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!